Effect of incretins on skeletal health.
Journal
Current opinion in endocrinology, diabetes, and obesity
ISSN: 1752-2978
Titre abrégé: Curr Opin Endocrinol Diabetes Obes
Pays: England
ID NLM: 101308636
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
medline:
3
7
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
The incretin hormones, glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have been shown to decrease bone resorption in humans. The aim of this review is to collate evidence and current advances in the research within the last year on the effect of incretins on skeletal health. Preclinical studies show potential direct beneficial effects on bone by GLP-1 and GIP, however real world epidemiological data show no effects of GLP-1 receptor analogues on fracture risk. This may be due to the weight loss accompanied by GLP-1 treatment which may have detrimental effects on bone. GIP is shown to reduce bone resorption and increase bone formation. Further evidence suggests an additive effect of GIP and glucagon like peptide-2, which could affect bone by different mechanisms. GIP and GLP-1 based therapies are more widespread used and may have potential beneficial effects on bone, possibly counterbalanced by weight loss. Long-term effects and side-effects of GIP or GIP/ GLP-2 co-administration remain to be elucidated, and longer term treatment trials are needed.
Identifiants
pubmed: 37334507
doi: 10.1097/MED.0000000000000813
pii: 01266029-202308000-00006
doi:
Substances chimiques
Incretins
0
Gastric Inhibitory Polypeptide
59392-49-3
Glucagon-Like Peptide 1
89750-14-1
Glucagon-Like Peptide-1 Receptor
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-212Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Kanis JA, Norton N, Harvey NC, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 2021; 16:82.
Adami G, Fassio A, Gatti D, et al. Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. Ther Adv Musculoskelet Dis 2022; 14: 1759720x221083541.
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 2007; 18:427–444.
Sølling ASK, Harsløf T, Langdahl B. Current status of bone-forming therapies for the management of osteoporosis. Drugs Aging 2019; 36:625–638.
Mabilleau G. Interplay between bone and incretin hormones: a review. Morphologie 2017; 101:9–18.
Wong E, Cope R, Dima L, Nguyen T. Tirzepatide: a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 agonist for the management of type 2 diabetes mellitus. Am J Ther 2023; 30:e26–e35.
Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr 2017; 30:202–210.
Schioldan AG, Gregersen S, Hald S, et al. Effects of a diet rich in arabinoxylan and resistant starch compared with a diet rich in refined carbohydrates on postprandial metabolism and features of the metabolic syndrome. Eur J Nutr 2018; 57:795–807.
Maagensen H, Helsted MM, Gasbjerg LS, et al. The gut-bone axis in diabetes. Curr Osteoporos Rep 2023; 21:21–31.
Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141:1228–1235.
Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol 2011; 11:12.
Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007; 292:E543–E548.
Hygum K, Starup-Linde J, Langdahl BL. Diabetes and bone. Osteoporos Sarcopenia 2019; 5:29–37.
Westberg-Rasmussen S, Starup-Linde J, Hermansen K, et al. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone 2017; 97:261–266.
Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18:2180–2189.
Clowes JA, Allen HC, Prentis DM, et al. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 2003; 88:4867–4873.
Skov-Jeppesen K, Veedfald S, Madsbad S, et al. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study. Bone 2021; 152:116065.
Nissen A, Marstrand S, Skov-Jeppesen K, et al. A pilot study showing acute inhibitory effect of GLP-1 on the bone resorption marker CTX in humans. JBMR Plus 2019; 3:e10209.
Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab 2021; 23: (Suppl 3): 5–29.
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65:1925–1966.
Hansen MS, Søe K, Christensen LL, et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur J Endocrinol 2023; (1):188.
Zhai S, Liu C, Vimalraj S, et al. Glucagon-like peptide-1 receptor promotes osteoblast differentiation of dental pulp stem cells and bone formation in a zebrafish scale regeneration model. Peptides 2023; 163:170974.
Wang M, Liu M, Zheng J, et al. Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment. Open Med (Wars) 2023; 18:20230692.
Lu Y, Liu S, Yang P, et al. Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway. Stem Cell Res Ther 2022; 13:113.
Shi S, Song S, Liu X, et al. Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats. Drug Deliv 2022; 29:548–560.
Nirwan N, Vohora D. Linagliptin in combination with metformin ameliorates diabetic osteoporosis through modulating BMP-2 and sclerostin in the high-fat diet fed C57BL/6 mice. Front Endocrinol (Lausanne) 2022; 13:944323.
Yang M, Pang Y, Pei M, et al. Therapeutic potential of liraglutide for diabetes-periodontitis comorbidity: killing two birds with one stone. J Diabetes Res 2022; 2022:8260111.
Abdi AM, Pasiou E, Konstantopoulos P, et al. Effects of incretin pathway elements on bone properties. Cureus 2023; 15:e33656.
Gobron B, Couchot M, Irwin N, et al. Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility. J Bone Miner Res 2023; 38:733–748.
Al-Mashhadi ZK, Viggers R, Fuglsang-Nielsen R, et al. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study. Front Endocrinol (Lausanne) 2022; 13:882998.
Al-Mashhadi ZK, Viggers R, Starup-Linde J, et al. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study. Front Endocrinol (Lausanne) 2022; 13:861422.
Xie FF, Zhang YF, Hu YF, et al. Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis. World J Clin Cases 2022; 10:1527–1535.
Torekov SS, Harsløf T, Rejnmark L, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 2014; 99:E729–E733.
Sonestedt E, Lyssenko V, Ericson U, et al. Genetic variation in the glucose-dependent insulinotropic polypeptide receptor modifies the association between carbohydrate and fat intake and risk of type 2 diabetes in the Malmo Diet and Cancer cohort. J Clin Endocrinol Metab 2012; 97:E810–E818.
Zhang L, He J, Sun X, et al. GIPR rs10423928 and bone mineral density in postmenopausal women in Shanghai. Endocr Connect 2022; 11: https://doi.org/10.1530/EC-21-0583
doi: 10.1530/EC-21-0583
Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, et al. Glucose-lowering drugs and fracture risk—a systematic review. Curr Osteoporos Rep 2020; 18:737–758.
Daniilopoulou I, Vlachou E, Lambrou GI, et al. The impact of GLP1 agonists on bone metabolism: a systematic review. Medicina (Kaunas) 2022; 58: https://doi.org/10.3390/medicina58020224
doi: 10.3390/medicina58020224
Huang CF, Mao TY, Hwang SJ. The effects of switching from dipeptidyl peptidase-4 inhibitors to glucagon-like peptide-1 receptor agonists on bone mineral density in diabetic patients. Diabetes Metab Syndr Obes 2023; 16:31–36.
Hygum K, Harsløf T, Jørgensen NR, et al. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 2020; 132:115197.
Iepsen EW, Lundgren JR, Hartmann B, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 2015; 100:2909–2917.
Iqbal J, Wu HX, Hu N, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev 2022; 23:e13435.
Johnson KC, Bray GA, Cheskin LJ, et al. The effect of intentional weight loss on fracture risk in persons with diabetes: results from the look AHEAD randomized clinical trial. J Bone Miner Res 2017; 32:2278–2287.
Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res 2012; 27:619–627.
Johansen NJ, Dejgaard TF, Lund A, et al. Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes Obes Metab 2022; 24:221–227.
Dalsgaard NB, Gasbjerg LS, Helsted MM, et al. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes. Bone 2023; 170:116687.
Lei WS, Kilberg MJ, Zemel BS, et al. Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis. J Clin Transl Endocrinol 2022; 30:100304.
Gabe MBN, Skov-Jeppesen K, Gasbjerg LS, et al. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacol Res 2022; 176:106058.
Heimbürger SMN, Hoe B, Nielsen CN, et al. GIP affects hepatic fat and brown adipose tissue thermogenesis but not white adipose tissue transcriptome in type 1 diabetes. J Clin Endocrinol Metab 2022; 107:3261–3274.
Chai S, Liu F, Yang Z, et al. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks. Front Pharmacol 2022; 13:825417.
Driessen JH, van Onzenoort HA, Starup-Linde J, et al. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other antihyperglycemic drugs. Pharmacoepidemiol Drug Saf 2015; 24:1017–1025.
Driessen JH, van Onzenoort HA, Starup-Linde J, et al. Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other antihyperglycemic drugs. Calcif Tissue Int 2015; 97:506–515.
Blüher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity. Diabetes Obes Metab 2023; 1–15. doi: 10.1111/dom.15077.
doi: 10.1111/dom.15077
Fuglsang-Nielsen R, Starup-Linde J, Gregersen S, Vestergaard P. The effect of meals on bone turnover - a systematic review with focus on diabetic bone disease. Expert Rev Endocrinol Metab 2018; 13:233–249.
Skov-Jeppesen K, Hepp N, Oeke J, et al. The antiresorptive effect of GIP, but not GLP-2, is preserved in patients with hypoparathyroidism—a randomized crossover study. J Bone Miner Res 2021; 36:1448–1458.